Oculis Holding AG Ordinary shares Total Liabilities
Oculis Holding AG Ordinary shares total liabilities. Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has total liabilities worth $39.94 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Oculis Holding AG Ordinary shares (OCS) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oculis Holding AG Ordinary shares (2020–2025)
Total liabilities of Oculis Holding AG Ordinary shares from 2020 to 2025. This chart illustrates how Oculis Holding AG Ordinary shares's total liabilities have evolved over time, based on quarterly financial data. Explore Oculis Holding AG Ordinary shares (OCS) long-term investment share to see how much of total assets are deployed in long-term investments.
Oculis Holding AG Ordinary shares Competitors by Total Liabilities
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
Germany | €713.83 Million |
|
Pes Camanchaca
SN:CAMANCHACA
|
Chile | CL$423.96 Million |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
Mexico | MX$21.16 Billion |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
China | CN¥831.08 Million |
|
Shenyang Chemical Industry Co Ltd
SHE:000698
|
China | CN¥3.74 Billion |
|
Haverty Furniture Companies Inc
NYSE:HVT
|
USA | $345.68 Million |
|
Plaza Retail REIT
TO:PLZ-UN
|
Canada | CA$716.56 Million |
|
Direct Finance TA
TA:DIFI
|
Israel | ILA8.95 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Oculis Holding AG Ordinary shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Oculis Holding AG Ordinary shares balance sheet assets.
Liquidity & Leverage Metrics
Oculis Holding AG Ordinary shares Total Liabilities Ratios Explained
Oculis Holding AG Ordinary shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oculis Holding AG Ordinary shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual total liabilities of Oculis Holding AG Ordinary shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $39.94 Million | -14.97% |
| 2024-12-31 | $46.97 Million | +127.73% |
| 2023-12-31 | $20.62 Million | -84.73% |
| 2022-12-31 | $135.05 Million | +13.49% |
| 2021-12-31 | $119.00 Million | +98.21% |
| 2020-12-31 | $60.04 Million | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more